Format

Send to

Choose Destination
Am J Transplant. 2016 May;16(5):1465-73. doi: 10.1111/ajt.13616. Epub 2016 Feb 8.

Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.

Author information

1
Division of Abdominal Transplantation, Department of Surgery, Dartmouth Hitchcock Medical Center, Hanover, NH.
2
Division of Abdominal Transplantation, Department of Surgery, Johns Hopkins University, Baltimore, MD.
3
Center for Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, MO.
4
Transplant Nephrology, Washington University School of Medicine, St. Louis, MO.
5
Division of Nephrology, University of Michigan, Ann Arbor, MI.
6
Department of Surgery, Brody School of Medicine, East Carolina University, Greenville, NC.
7
Division of Nephrology, Department of Medicine, Saint Louis University School of Medicine, St. Louis, MO.

Abstract

The infrequent use of ABO-incompatible (ABOi) kidney transplantation in the United States may reflect concern about the costs of necessary preconditioning and posttransplant care. Medicare data for 26 500 live donor kidney transplant recipients (2000 to March 2011), including 271 ABOi and 62 A2-incompatible (A2i) recipients, were analyzed to assess the impact of pretransplant, transplant episode and 3-year posttransplant costs. The marginal costs of ABOi and A2i versus ABO-compatible (ABOc) transplants were quantified by multivariate linear regression including adjustment for recipient, donor and transplant factors. Compared with ABOc transplantation, patient survival (93.2% vs. 88.15%, p = 0.0009) and death-censored graft survival (85.4% vs. 76.1%, p < 0.05) at 3 years were lower after ABOi transplant. The average overall cost of the transplant episode was significantly higher for ABOi ($65 080) compared with A2i ($36 752) and ABOc ($32 039) transplantation (p < 0.001), excluding organ acquisition. ABOi transplant was associated with high adjusted posttransplant spending (marginal costs compared to ABOc - year 1: $25 044; year 2: $10 496; year 3: $7307; p < 0.01). ABOi transplantation provides a clinically effective method to expand access to transplantation. Although more expensive, the modest increases in total spending are easily justified by avoiding long-term dialysis and its associated morbidity and cost.

PMID:
26603690
PMCID:
PMC4844838
DOI:
10.1111/ajt.13616
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center